Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Non-small Cell Lung Cancer × osimertinib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 152 Lung Neoplasms 48 NSCLC 11 Neoplasms 9 Neoplasm Metastasis 9 Brain Neoplasms 7 Carcinoma 6 Bronchial Neoplasms 5 Thoracic Neoplasms 4 Respiratory Tract Neoplasms 3 Respiratory Tract Diseases 3 Neoplasms by Site 3 Meningeal Carcinomatosis 3 Lung Diseases 3 Colorectal Neoplasms 3 Adenocarcinoma of Lung 3 Adenocarcinoma 3 Noonan Syndrome 2 Non Small Cell Lung Cancer Metastatic 2 Neoplasms, Nerve Tissue 2 Neoplasms by Histologic Type 2 Carcinoma, Squamous Cell 2 Carcinoma, Bronchogenic 2 Breast Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 T790M Positive NSCLC Patients 1 Stage II-IIIB Non-small Cell Lung Carcinoma 1

Interventions

Docetaxel 4 pembrolizumab 3 Pemetrexed 3 Nivolumab 2 Cisplatin 2 Carboplatin 2 tislelizumab 1 rofecoxib 1 paclitaxel poliglumex 1 osimertinib 1 nazartinib 1 lenvatinib 1 cemiplimab 1 aumolertinib 1 atezolizumab 1 anlotinib 1 aflutinib 1 abivertinib 1 Rosuvastatin Calcium 1 Radiosurgery 1 RO5126766 1 Platinum Compounds 1 Midazolam 1 Gemcitabine 1 Gefitinib 1 Food 1 Esomeprazole 1 Drug Therapy 1 Dabigatran 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05489731 2023-06-15

VIC-1911

Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.

Phase 1 Unknown

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡